Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefoxitin: a hospital study

A M Geddes, L P Schnurr, A P Ball

    British Medical Journal
    |April 30, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Life after abciximab; what's next for intracoronary thrombus?

    Journal of thrombosis and thrombolysis·2019
    Same author

    Physicians and Infection.

    Journal of the Royal College of Physicians of London·2019
    Same author

    Kinematic stride cycle asymmetry is not associated with sprint performance and injury prevalence in athletic sprinters.

    Scandinavian journal of medicine & science in sports·2017
    Same author

    A new look at infectious diseases: enteric Fever, salmonellosis, and food poisoning.

    British medical journal·2010
    Same author

    Influenza and bacterial pneumonia.

    International journal of antimicrobial agents·2009
    Same author

    The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA).

    International journal of antimicrobial agents·2006
    Same journal

    Muscular pain during therapy with carbenoxolone (Biogastrone).

    British medical journal·2016
    Same journal

    ACUTE INTESTINAL OBSTRUCTION DUE TO INTRA-ABDOMINAL CAUSES.

    British medical journal·2014
    Same journal

    A CASE OF HAEMATIDROSIS.

    British medical journal·2014
    Same journal

    Incidence of ulcer in haematemesis.

    British medical journal·2011
    Same journal

    Pituitary hypothyroidism with impaired renal function.

    British medical journal·2011
    Same journal

    The fenestration operation for otosclerosis.

    British medical journal·2011
    See all related articles

    Cefoxitin, a new cephamycin antibiotic, showed promising results in treating acute infections. This study found cefoxitin effective in most patients, with high drug concentrations supporting its use for serious Gram-negative infections.

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Clinical Microbiology

    Background:

    • Cephamycin antibiotics represent a novel class of antimicrobial agents.
    • Cefoxitin has recently been introduced for clinical investigation.
    • Acute infections pose significant challenges in hospital settings.

    Purpose of the Study:

    • To evaluate the clinical efficacy of cefoxitin in treating various acute infections.
    • To assess the pharmacokinetic profile of cefoxitin in patients.
    • To determine the potential role of cefoxitin in managing serious bacterial infections.

    Main Methods:

    • An uncontrolled clinical trial was conducted.
    • Thirty-one hospitalized patients with acute infections received cefoxitin treatment.

    Related Experiment Videos

  • Serum, urine, and bile concentrations of cefoxitin were measured and compared to MICs.

    • Main Results:

    • Twenty out of 31 patients (64.5%) achieved clinical cure.
    • Cefoxitin concentrations in serum, urine, and bile significantly exceeded the minimum inhibitory concentration (MIC) for key Gram-negative pathogens.
    • The antibiotic demonstrated effective penetration into various bodily fluids.

    Conclusions:

    • Cefoxitin is a promising antibiotic for managing serious infections.
    • Its efficacy is particularly noted in abdominal cavity and renal tract infections.
    • High drug concentrations support its therapeutic potential against Gram-negative organisms.